Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,301.20
(
-1.77%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
108.19
(
3.60%
)
Bitcoin
69,783.41
(
-0.17%
)
News Focus
News Focus
Post# of 257263
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122805
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 107199

Monday, 10/25/2010 7:12:11 PM

Monday, October 25, 2010 7:12:11 PM

Post# of 257263
This is a low-risk undertaking by VRTX/JNJ. Assuming that patient compliance is strong (as it ought to be in an open-label clinical setting where there are no superfluous placebo pills), the only underlying scientific issue is the PK profile of Telaprevir, which by now is well understood. With a typical non-inferiority margin for this kind of study, the likelihood of a non-inferiority finding is very high, IMO.

Any guesses on the quiz question in #msg-55918145?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up